GWPH's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 921.1 -- higher than 95.72% of US-listed equities with positive expected earnings growth.
The ratio of debt to operating expenses for Gw Pharmaceuticals Plc is higher than it is for about just 7.93% of US stocks.
Revenue growth over the past 12 months for Gw Pharmaceuticals Plc comes in at 133.62%, a number that bests 95.7% of the US stocks we're tracking.
If you're looking for stocks that are quantitatively similar to Gw Pharmaceuticals Plc, a group of peers worth examining would be AIRG, SWAV, OOMA, PRO, and AEHR.
GWPH's SEC filings can be seen here. And to visit Gw Pharmaceuticals Plc's official web site, go to www.gwpharm.com.
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company was founded in 1998 and is based in Cambridge, the United Kingdom.
In August 2019, I wrote a somewhat negative article on Ovid Therapeutics (OVID) and its OV101 drug. I said that OV101 failed to meet statistical significance in a number of secondary efficacy endpoints in a phase 2 trial, so I doubted how it would fare in the then-ongoing phase 3...
Avisol Capital Partners on Seeking Alpha | January 18, 2021
Cannabis stocks widely outperformed the markets after a slew of financing deals and strong earnings reports."The cannabis industry is off to a great start this year with New York state pushing hard for legalization," Green Market Report editor-in-chief Debra Borchardt said. "In addition to that several companies like GrowGeneration and GW Pharmaceuticals reported stellar earnings. Plus, Subversive Capital closed on the largest SPAC in the industry. Hopefully, the good news in 2021 will continue unlike the curveball thrown at us in 2020."ETFs were all up by double digits. Over the last five trading days: * The ETFMG Alternative Harvest ETF (NYSE: MJ): gained almost 18% * The AdvisorShares Pure Cannabis ETF (NYSE: YOLO): was up almost 12% * The Cannabis ETF (NYSE: THCX): rose 18.4% * ...
United Kingdom-based GW Pharmaceuticals expects to report annual sales of approximately $526 million for the year ended Dec. 31, 2020, it said in a preview of its fourth quarter and full-year results. Fourth quarter net sales will be approximately $148 million, based on preliminary unaudited financial information, GW said in a news release this week. […] GW Pharma expects fiscal 2020 sales to reach $526 million is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs
The Democratic win that joined the wave of state legalization is encouraging for the cannabis market. Based on their most recent quarterly filing, Canopy Growth Corp (NASDAQ: CGC ), Cronos Group Inc (NASDAQ: CRON ), GW Pharmaceuticals PLC (NASDAQ: GWPH ), Aphria Inc (NASDAQ: APHA ) that announced it will merge with Tilray Inc (NASDAQ: TLRY ) in mid-December and Trulieve Cannabis Corp (OTC: TCNNF ), entered 2021 with the most cash on their balance sheets. But other stocks such as Curaleaf Holdings Inc (OTC: CURLF ), Cresco Labs Inc (OTC: CRLBF ), Planet 13 Holdings Inc (OTC: PLNHF ), Innovative Industrial Properties Inc (NYSE: IIPR ) and Green Thumb Industries Inc (OTC: GTBIF ) show a lot of potential as well, along with several powerful small caps. Being Cash-Rich Is Not Is As It Seems ...